



PATENT
Attorney Docket No. (468330-1810) 33828/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

MARINKOVICH

Serial No. 10/766,317

Filed: January 27, 2004

For: *Compositions and Methods for
Inhibiting Squamous Cell
Carcinoma*

Examiner: TIDWELL, JUDY LILLE

Art Unit: 1642

CERTIFICATE OF MAILING: I hereby certify that this document is being sent via first class U.S. mail with sufficient postage addressed to: Mail Stop AMENDMENT, Commissioner for Patents, P. O. Box 1450, Alexandria, Virginia 22313-1450 on

March 29, 2006



Victoria Linne Poulsen

INFORMATION DISCLOSURE STATEMENT

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying form PTO/SB/8A. In accordance with 1287 Off. Gaz. Pat. Office 163, 10/19/2004, no copies of U.S. patents and U.S. published applications are enclosed. Copies of foreign patents and non-patent literature are enclosed.

Further, in accordance with the provision of 37 C.F.R. §§ 1.97(c) and 1.97(e)(1), the undersigned certifies that references A38, B1, B2 and C51, C55 and C82 listed on the enclosed form PTO-SB/8A(1449) were cited in the International Search Report dated September 7, 2005, for a counterpart PCT application, PCT Application No. PCT/US2005/001575. A copy of the International Search Report for the counterpart PCT application is enclosed herewith.

As far as is known to the undersigned, this Information Disclosure Statement is being filed within three months of the filing date of a national application, within three months of the date of entry of the

national state in an international application, or before the mailing date of a first Office Action on the merits as set forth in 37 C.F.R. § 1.97(b), and therefore no fee is required

Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application. Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

The Commissioner is authorized to charge any additional fees including extension fees, or other relief that may be required, or credit any overpayment to Deposit Account No. 50-2319 (Order No. (468330-1810) 33828/US/RFT/RMK).

Respectfully submitted,

DORSEY & WHITNEY LLP

By:



Richard F. Trecartin, Reg. No 31,801
Filed under 37 C.F.R. § 1.34
Customer No. 32940

Dated: March 29, 2006

555 California Street
Suite 1000
San Francisco, California 94104-1513
Telephone: (415) 781-1989
Fax No. (415) 398-3249

4836-9748-1216\13/29/2006 10:42 AM



Substitute PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
(Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	5	Attorney Docket Number	Docket 33828/US
-------	---	----	---	------------------------	-----------------

Complete if Known

Application Number	10/766,317
Filing Date	January 27, 2004
First Named Inventor	Marinkovich
Art Unit	1642
Examiner Name	TIDWELL, JUDY LILLE

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	U.S. Pat. Pub. No. 2002/0076736	06-20-2002	Findell et al.	
	A2	US-4816567	03-28-1989	Cabilly et al.	
	A3	US-6294356	09-25-2001	Jones et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1	WO0026342 A	5-11-2000	Northwestern University		
	B2	WO0187239 A	11-22- 2001	Fibrogen, Inc. et al.		
	B3	WO 96/04000	02-15-1996	Shah et al.		
	B4	WO 91/04753	04-18-1991	Baer et al.		
	B5	WO 90/10448	09-20-1990	Bischofberger et al.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C1	Ahmed et al. "Chapter 39, Immunity to Viruses" <i>Fundamental Immunology</i> , 4th edition, W. E. Paul, ed., Lippincott-Raven Publishers, 1999, Chapter 39, pp 1295-1334	
	C2	Alama et al."Antisense Oligonucleotides as Therapeutic Agents" (1997) <i>Pharmacol Res.</i> 36(3):171-178	
	C3	Amano et al., "Bone morphogenetic protein 1 is an extracellular processing enzyme of the Laminin 5Y2 chain" 2000, <i>J. Biol. Chem.</i> , 275: 22728-35	
	C4	Boado et al., "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS" 1998, <i>J. Pharm. Sci.</i> 87 (11): 1308-1315	
	C5	Cassidy et al., "Malignant cells adhere to and synthesize laminin-5 <i>n vitro</i> " <i>Ep. Derm.</i> 1999, 8, 212-221	
	C6	Chan et al. "Laminin-6 and Laminin-5 are recognized by Autoantibodies in a subset of cicatricial pemphigoid" <i>Society for Invs. Derm.</i> , 1997, 848-853	
	C7	Chen et al. "NC1 Domain of Type VII Collagen Binds to the β 3 chain of laminin 5 via a Unique Subdomain Within the Fibronectin-like repeats" (1999) <i>J. for Invest. Derm.</i> , 177-183	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
(Modified)**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/766,317
Filing Date	January 27, 2004
First Named Inventor	Marinkovich
Art Unit	1642
Examiner Name	TIDWELL, JUDY LILLE

Sheet **2** of **5** Attorney Docket Number **Docket 33828/US****NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C8	Crooke, S. T., "Advances in understanding the pharmacological properties of antisense oligonucleotides" 1997, <i>Adv. Pharmacol.</i> 40:1-49	
	C9	Dajee et al., "NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia" <i>Nature</i> vol. 421, 2003, 639-643	
	C10	Diederichsen, U., "Alanyl-PNA homoduplex: A-T Pairing with the N7-Regiosomer of Adenine" 1998, <i>Bioorganic & Med. Chem. Lett.</i> , 8:165-168	
	C11	Fukushima et al., "Integrin α3β1-mediated interaction with laminin-5 stimulates adhesion, migration and invasion of malignant glioma cells" 1998, <i>Int. J. Cancer</i> , 76: 63-72	
	C12	Huse et al., "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda" 1989, <i>Science</i> , 254: 1275-1281	
	C13	Jordan et al., "New Hetero-oligomeric peptide nucleic acids with improved binding properties to complementary DNA" (1997) <i>Bioorg. Med. Chem. Lett.</i> 7: 687-690	
	C14	Jordan et al. "Synthesis of new building blocks for peptide nucleic acids containing monomers with variations in the backbone" (1997) <i>Bioorg. Med. Chem. Lett.</i> 7: 637-627;	
	C15	Kirtschig et al. "Anti-basement membrane autoantibodies in patients with anti-peiligrin cicatricial pemphigoid bind the α subunit of laminin 5", <i>J. Invest. Derm.</i> (1995) 105, 543-548	
	C16	Kumar et al., "Pyrrolidine Nucleic Acids: DNA/PNA Oligomers with 2-hydroxy/aminoethyl-4(thymin-1-yl) pyrrolidine-N-acetic acid" 2001, <i>Organic Letters</i> 3(9): 1269-1272	
	C17	Lavrosky et al., "Therapeutic potential and mechanism of action of oligonucleotides and ribozymes" 1997, <i>Biochem. Mol. Med.</i> 62(1):11-22.	
	C18	Lee et al., "Polyamide Nucleic Acid Targeted to the Primer Binding Site of the HIV-1 RNA Genome Blocks <i>in vitro</i> HIV-1 Reverse Transcription" 1998, <i>Biochemistry</i> 37 (3):900-1010	
	C19	Li et al. "Laminin-10 is crucial for hair morphogenesis" <i>The EMBO Journal</i> , vol. 22, no. 10, pp. 2400-2410	
	C20	Maddox et al., "Elevated serum levels in human pregnancy of a molecule immunochemically similar to eosinophil granule major basic protein" 1983, <i>J Exp Med</i> , 158: 1211	
	C21	Marcus-Sakura "Techniques for using antisense oligodeoxyribonucleotides to study gene expression" (1988) <i>Anal. Biochem.</i> 172:289	
	C22	Marinkovich et al. "Basement Membrane Proteins Kalinin and Nicein are Structurally and Immunologically Identical: <i>Lab. Invest.</i> , 1993, vol. 69, No. 3, pp. 295-299	
	C23	Marinkovich et al., "The dermal-epidermal junction of human skin contains a novel laminin variant" <i>J. Cell. Biol.</i> vol. 119, no. 3, 1992, 695-703	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
(Modified)**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/766,317
Filing Date	January 27, 2004
First Named Inventor	Marinkovich
Art Unit	1642
Examiner Name	TIDWELL, JUDY LILLE

Sheet

3

of

5

Attorney Docket Number

Docket 33828/US**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C241	Marinkovich M. P. et al, "The Anchoring Filament Protein Kalinin is Synthesized and Secreted as a High Molecular Weight Precursor", <i>Journal of Biological Chemistry</i> , vol. 267, no. 25, 1992, pages 17900-17906	
	C25	McGowan et al. "Laminins and human disease" <i>Microscopy Res. and Tech.</i> 51::262-279 (2000)	
	C26	Meneguzzi et al. "Kalinin is abnormally expressed in epithelial basement membranes of Herlitz's junctional epidermolysis bullosa patients" <i>Exp. Derm.</i> 1992, pp. 221-229	
	C27	Meneguzzi et al., "Kalinin is abnormally expressed in epithelial basement membranes of Herlitzs junctional epidermolysis bullosa patients", 1992, <i>Exp. Derm.</i> 1, 221-229	
	C28	Miller, "Progress Toward Human Gene Therapy" 1990, <i>Blood</i> , 76: 271	
	C29	Miquel et al., "Establishment and Characterization of cell line LSV5 that retains the altered adhesive properties of human junctional epidermolysis bullosa keratinocytes, <i>Exp. Cell. Res.</i> , 224, 279-290 (1996)	
	C301	Mizushima H. et al., Identification of Integrin-dependent and independent cell adhesion domains in cooh-terminal globular region of alminin-5 alpha3 chain" <i>Cell Growth and Differentiation</i> , The Association, Phil. Pa, US, Vol. 8, no. 9, September 1997 (1997-09), pages 979-987	
	C31	Morris et al., "A new peptide vector for efficient delivery of oligonucleotides into mammalian cells" 1997, <i>Nucl. Acids Res.</i> 25 (14): 2730-2736	
	C32	Nielsen, P. E. and G. Haaima, "Peptide nucleic acid (PNA). a DNA mimic with a pseudopeptide backbone" 1997, <i>Chem. Soc. Rev.</i> 96:73-78	
	C33	O'Toole et al. "Laminin-5 inhibits human keratinocyte migration" <i>Exp. Cell. Res.</i> 233, 330-339 (1997)	
	C34	Orlandi et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction" 1989, <i>Proc. Natl. Acad. Sci.</i> 86: 3833-3837	
	C35	Ortiz-Urda et al. "Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue" <i>J. Clin. Invest.</i> 2003, Vol. 111, No. 2, pps. 251-255	
	C36	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier <i>in vivo</i> " 1995, <i>Proc. Nat. Acad. Sci.</i> 92 (12):5592-5596	
	C37	Pyke et al., "Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas" 1995, <i>Canc. Res.</i> 55: 4132-4139; Berndt et al., 1997, <i>Invasion and Metastasis</i> , 17: 251-258	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Sheet	4	of	5	Attorney Docket Number	Docket 33828/US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	C38	Pyke, et al., "The γ2 chain of kalinin/Laminin 5 is preferentially expressed in invading malignant cells in human cancers" 1994, <i>Am. J. Pathol.</i> 145(4):782-791			
	C39	Rammensee, H., et al. "SYFPEITHI: database for MHC ligands and peptide motifs": (1999) <i>Immunogenetics</i> , 50:213-219			
	C40	Rossi et al., "Exploring the use of antisense, enzymatic RNA molecules (Ribozymes) as therapeutic agents" 1991, <i>Antisense Res. Dev.</i> 1(3):285-288			
	C41	Rossi, "Therapeutic antisense and ribozymes" 1995, <i>Br. Med. Bull.</i> 51 (1): 217-225			
	C42	Russell et al., "α6β4 integrin regulates keratinocyte chemotaxis through differential GTPase activation and antagonism of α3β1 integrin" 2003, <i>J. Cell Sci.</i> 116 (17)3543-3556			
	C43	Ryan et al. "Cloning of the LamA3 Gene Encoding the alpha3 chain of the adhesive ligand epiligrin" <i>J.Bio. Chem.</i> vol. 269, no. 36, pp. 22779-22787 (1984)			
	C44	Slater et al., "The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine" 1998, <i>J. Allergy Cli. Immunol.</i> 102 (3): 469-475			
	C45	Stoltzfus P. et al., "Lamin-5 Gamma2 Chain Expression Facilitates Detection of Invasive Squamous Cell Carcinoma of the Uterine Cervix, <i>International Journal of Gynecological Pathology</i> , Vol. 23, no. 3, July 2004 (2004-07), pages 215-222			
	C46	Uckert and Walther, "Retrovirus-mediated gene transfer in cancer therapy" 1994, <i>Pharmacol. Ther.</i> , 63(3): 323-347			
	C47	van Hest et al., "Efficient introduction of alkene functionality into proteins in vivo" <i>FEBS Lett</i> 428:(1-2) 68-70 May 22 1998			
	C48	Veitch et al., "Mammalian Tolloid Metalloproteinase, and not matrix metalloprotease 2 or membrane type 1 metalloprotease, processes laminin-5 in keratinocytes and skin" 2003, <i>J. Biol. Chem.</i> , 278: 15661-15668			
	C49	Verhoeyen et al., "Reshaping human antibodies: grafting an antilysozyme activity" 1988, <i>Science</i> , 239: 1534-1536			
	C50	Weinberg et al. "How cancer arises: an explosion of research in uncovering the long-hidden molecular underpinnings of cancer and suggesting new therapies" <i>Scientific American</i> (1996) (September) pps 62-70			
	C51	Winter, G. and C. Milstein, "man-made intibodies" 1991, <i>Nature</i> , 349: 293-299			
	C52	Yi-shan et al. "Self-assembly of Laminin Isoforms" <i>J. Bio. Chem.</i> vol. 272, no. 50, pp 31525-31532 (1997)			

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	«ApplicationNo»
				Filing Date	«FilingDate»
				First Named Inventor	«M_1stInventor» «etal»
				Group Art Unit	«ArtUnit»
				Examiner Name	«Examiner»
Sheet	5	of	5	Attorney Docket Number	«FlehrFileNo»/«AttorneyInitials»/«OtherInitials»

4844-8489-7024\13\7\2006 11:56 AM

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
